rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Nautilus Biotechnology, Inc.

NAUT · Nasdaq

Health CareLife-science toolsAbove a falling average

NAUT stood above a rising 150-day average in 31 of the last 52 weekly readings, and has been out of that trend for the last 20 weeks. It is 26.2% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+1 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 20
Industry in uptrend
52% +1 in 4 wk
Insider buys, 12 months
$136K
Insider sales, 12 months
$23.5M
Officials’ trades on record
0
Institutions holding
86 (+13)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 31 of 52 weeks.

21 Apr – 20 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$22.6M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months2
Buyers · sellers2 · 2
WhoDidSharesTraded
Ah Equity Partners Bio Ii, L.l.c.10% ownersold4,615,974at $2.352 Jun 2026filed 4 Jun 2026
Ah Equity Partners Bio Ii, L.l.c.10% ownersold384,026at $2.352 Jun 2026filed 4 Jun 2026
Sujal M. PatelCEO, President, and Secretarybought25,000at $2.614 Mar 2026filed 4 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders86+13 on the quarter
New · exited29 · 17
Reported value$89.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
PERCEPTIVE ADVISORS LLCreduced · filed 14 Aug 202611,634,211$21.8M-960,000−7.6%
a16z Capital Management, L.L.C.reduced · filed 14 Aug 20269,063,054$16.9M-8,590,863−48.7%
Cercano Management LLCunchanged · filed 13 Aug 20267,172,985$13.4M00.0%
BlackRock, Inc.added · filed 7 Aug 20262,687,226$5.0M+2,499,555+1331.9%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,549,979$4.8M+4,382+0.2%
Comprehensive Financial Management LLCunchanged · filed 14 Aug 20262,207,619$4.1M00.0%
CITADEL ADVISORS LLCnew · filed 14 Aug 20261,896,192$3.5M+1,896,192
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,265,535$2.4M+662,011+109.7%
Clearstead Advisors, LLCreduced · filed 6 Aug 2026892,787$1.7M-1,436,997−61.7%
SUSQUEHANNA INTERNATIONAL GROUP, LLPnew · filed 14 Aug 2026890,949$1.7M+890,949
31 Mar 2023 – 30 Jun 2026
557085Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Epperly Melissa B Company insiderDirector · last 18 Jun 20260 · 0
Farzad Nazem Company insiderDirector · last 18 Jun 20260 · 0
Karen Akinsanya Company insiderDirector · last 18 Jun 20260 · 0
Matthew L. Posard Company insiderDirector · last 18 Jun 20262 · 0
Matthew S. McIlwain Company insiderDirector · last 18 Jun 20264 · 0
AH Bio Fund II, L.P. Company insider10% owner · last 2 Jun 20260 · 1
AH Equity Partners Bio II, L.L.C. Company insider10% owner · last 2 Jun 20260 · 1
Sujal M. Patel Company insiderCEO, President, and Secretary · last 4 Mar 202616 · 0
Anna Mowry Company insiderCFO and Treasurer · last 2 Mar 20265 · 0
Gwen E. Weld Company insiderChief People Officer · last 2 Mar 20261 · 0
Kentaro Suzuki Company insiderChief Marketing Officer · last 2 Mar 20261 · 0
Matthew B. Murphy Company insiderGeneral Counsel · last 2 Mar 20264 · 0

Same industry

OABI OmniAbLeading+75%
TXG 10x GenomicsLeading+61%
AVTR AvantorLeading+48%
ILMN IlluminaLeading+46%
RVTY RevvityLeading+39%
MASS 908 DevicesLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 19 Feb 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$12.4M
Free cash flowFY 2025 · to 31 Dec 2025−$52.0M

Analyst forecasts

No analyst forecasts yet.